A Study of BGM0504 in Participants With Type 2 Diabetes

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 553 participants.

Also called NCT06716216

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 553 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT06716216
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
China (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT06716216. Randomized; no masking; primary purpose treatment. Start 2025-01-13 (actual); primary completion 2026-08-25 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study of BGM0504 in Participants With Type 2 Diabetes
Condition
Type 2 Diabetes Mellitus (T2DM)
Intervention (Drug)
Drug: 5 mg BGM0504 Administered SC
Intervention (Drug)
Drug:10 mg BGM0504 Administered SC
Intervention (Drug)
Drug: Semaglutide Administered SC
Lead sponsor
BrightGene Bio-Medical Technology Co., Ltd. (class: industry)
Collaborator
BrightGene New Bio-Medical Technology(Wuxi) Co.Ltd. (class: industry)

Record details

Record id
cardio:ct-nct06716216
Content hash
a7678ea5e1562fe7a0f1d4964734dd5144b6a3e045fac3bcdd8aecaa2f2b4720